Better Biopharma Latest Episode Cell & Gene

1. Building An Oral Vaccine Platform With Vaxart's Sean Tucker, Ph.D. 12/2/2025

   n this episode of “Better Biopharma,” host Tyler Menichiello is joined by Sean Tucker, Ph.D., founder and chief scientific officer at Vaxart, a company developing oral recombinant pill vaccines.

2. Lessons In Scaling Regenerative Medicine Manufacturing With Organogenesis's Patrick Bilbo 11/18/2025

   In this episode of "Better Biopharma," Tyler Menichiello is joined by Patrick Bilbo, chief operating officer at Organogenesis, a regenerative medicine company developing and manufacturing advanced wound care products.

3. Navigating The Complexity of Conditionally Active Biologics With Bonum Therapeutics' Diane Hollenbaugh, Ph.D., and Neela Patel, Ph.D. 10/31/2025

   In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. 

4. Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D. 10/20/2025

   In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.

5. Engineering Bacterial Vector-Based Immunotherapies With OS Therapies' Paul Romness and Robert Petit, Ph.D. 10/7/2025

   In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma.

6. How J&J Is Tackling Alzheimer's Disease With Fiona Elwood, Ph.D. 9/22/2025

   Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold Leader at Johnson & Johnson, explains the company’s modality-agnostic approach to treating Alzheimer’s disease in this episode of Better Biopharma.

7. CDMO Hunger Games And The State Of Biotech With Siren Biotechnology's Nicole Paulk, Ph.D. 9/9/2025

   Biotech leader Nicole Paulk, Ph.D., joins “Better Biopharma” to discuss Siren Biotechnology’s switch from plasmids to producer cell lines, CGT funding challenges, and the competition that determined which CDMO won Siren’s business.

8. Delivering Biologics To The Brain With Adaptin Bio's Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD 8/26/2025

   In this episode of "Better Biopharma," host Tyler Menichiello is joined by Adaptin Bio's CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD to discuss Adaptin's Brain Bispecific T-cell Engager (BRiTE) platform.

9. Developing An In Vivo CAR-T With Interius BioTherapeutics' Sianny Christanti and Babu Medi, Ph.D. 8/12/2025

   On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.

10. Functional Antibody Screening With Abalone Bio's Richard Yu, Ph.D. 7/29/2025

    In this episode of "Better Biopharma," Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening.